SAB BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.01 USD | +0.25% |
|
-0.50% | -41.67% |
| May. 06 | SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors | CI |
| Apr. 16 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 36.99M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.93
x | P/E ratio 2025 * |
-0.65
x | Employees | 57 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.39% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.25% | ||
| 1 week | -0.50% | ||
| Current month | -6.53% | ||
| 1 month | -10.89% | ||
| 3 months | -32.83% | ||
| 6 months | -58.67% | ||
| Current year | -41.67% |
1 week
3.94
4.50
1 month
3.944.94
Current year
3.947.00
1 year
3.9410.50
3 years
3.66129.00
5 years
3.66129.00
10 years
3.66129.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 21-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 21-10-21 |
Michael King
DFI | Director of Finance/CFO | 63 | 23-10-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 21-10-21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 21-10-21 |
Erick Lucera
BRD | Director/Board Member | 57 | 23-04-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 4.01 | +0.25% | 4,830 |
| 24-05-09 | 4 | -2.44% | 4,024 |
| 24-05-08 | 4.1 | +0.24% | 8,954 |
| 24-05-07 | 4.09 | +3.81% | 14,549 |
| 24-05-06 | 3.94 | -2.23% | 13,187 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.01
USD
Average target price
15.5
USD
Spread / Average Target
+286.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.67% | 36.99M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- SABS Stock